Glo-BNHL: a phase 2 and 3 trial testing odronextamab and loncastuximab tesirine in young people with relapsed or refractory B-cell non-Hodgkin lymphoma

Trial aim and background  

The aim of this trial is to look at two targeted drugs called odronextamab and loncastuximab tesirine for treating children and young people with relapsed or refractory B-cell nHL. 

Odronextamab is a type of treatment called a bispecific antibody. This is a targeted treatment which attaches to two different targets on the cancer cell. 

Loncastuximab tesirine is a type of treatment called an antibody drug conjugate. It is made up a monoclonal antibody which sticks to the cancer cell, and a chemotherapy medication which kills the cell. 

People in the trial will either have odronextamab or loncastuximab tesirine with modified RICE chemotherapy.

The trial aims to see how well the treatments work, how safe they are and what the side effects may be.

Who can enter 

Children and young people up to the age of 25 with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, primary mediastinal large B-cell lymphoma or not otherwise specified mature B-cell lymphoma may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

• Birmingham
• Bristol
• Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-treatment-for-b-cell-non-hodgkin-lymphoma-that-has-got-worse-glo-bnhl

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.